Brexpiprazole: A Partial Dopamine Agonist for the Treatment of Schizophrenia

(E-pub Ahead of Print)

Author(s): Asli Ekinci*, Okan Ekinci.

Journal Name:Reviews on Recent Clinical Trials

Volume 12 , 2017

Abstract:

BACKGROUND: Schizophrenia is a chronic and debilitating mental disorder that affects the patient’s and their family’s life. The disease remains a complicated disorder that is challenging to treat, despite there being a large antipsychotic armamentarium. Brexpiprazole acts both as a partial agonist at the serotonin 5-HT1A and dopamine D2 receptors and as an antagonist at the serotonin 5-HT2A and noradrenaline alpha1B and alpha2C receptors, all with similar potency. This balanced receptor profile may produce promising antipsychotic effects on positive, negative and cognitive symptoms in schizophrenia with minimal adverse effects. METHODS: This review summarizes the pharmacodynamics and pharmacokinetic profile of brexpiprazole and the clinical trial information pertaining to its effectiveness and safety and tolerability, discusses its best clinical use, and compares its clinical profile to those of other widely used antipsychotic agents. RESULTS: Brexpiprazole demonstrated significant clinical efficacy and had good safety and tolerability in well-designed trials with patients with schizophrenia. This agent may be a useful treatment alternative. CONCLUSION: However, it will be valuable to consider a long-term observational study that includes an active comparator, especially other second-generation antipsychotics (SGAs), to further evaluate the efficacy and safety of brexpiprazole in the treatment of schizophrenia.

Keywords: Brexpirazole, metabolism, schizophrenia, pharmacological interaction, pharmacokinetics

Rights & PermissionsPrintExport

Article Details

VOLUME: 12
Year: 2017
(E-pub Ahead of Print)
DOI: 10.2174/1574887112666170821114831
Price: $95